[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336502-105":59,"doc-detail-336502-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-the-management-of-colorectal-cancer-with-peritoneal-metastasis-a-single-center-cohort-study","Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Cancer with Peritoneal Metastasis - A Single-Center Cohort Study","","Multimodal treatment for peritoneal metastases (PM) from colorectal neoplasms may enhance overall survival (OS). This single-center retrospective cohort assessed cytoreductive surgery (CRS) combined with intraperitoneal chemohyperthermia (HIPEC) for colorectal cancer PM, with the primary aim of evaluating OS. Using outcomes from the Prodige 7 trial and an entropy-balance approach, a pseudopopulation tested CRS alone. Among 55 patients treated between March 2004 and January 2023, median OS was 47 months; 1-, 3-, and 5-year survival rates were 90.8%, 58.7%, and 42.7%.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-the-management-of-colorectal-cancer-with-peritoneal-metastasis-a-single-center-cohort-study/336502/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-the-management-of-colorectal-cancer-with-peritoneal-metastasis-a-single-center-cohort-study/336502.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment combination was evaluated for colorectal cancer patients with peritoneal metastases?","Question",{"text":112,"@type":113},"The study evaluated cytoreductive surgery (CRS) combined with intraperitoneal chemohyperthermia (HIPEC) as a multimodal strategy for peritoneal metastases from colorectal neoplasms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was overall survival (OS) assessed and what were the key survival outcomes?",{"text":117,"@type":113},"Overall survival was evaluated in a retrospective analysis of 55 treated patients. Median OS was 47 months, with 1-, 3-, and 5-year survival rates of 90.8%, 58.7%, and 42.7%, respectively.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the study suggest about prognostic factors such as PCI and completeness of cytoreduction?",{"text":121,"@type":113},"The findings emphasize the critical role of complete cytoreduction to achieve the best OS. PCI > 6 was identified as the most important prognostic factor influencing OS, and best results were described for relatively low PCI when a CCS ≤ 1 could be achieved.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336502,1790338815,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","medicina  \nArticle  \nCytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Cancer with Peritoneal Metastasis: A Single-Center Cohort Study  \nFabrizio D’Acapito 1, *, Massimo Framarini 1, Daniela Di Pietrantonio 1, Francesca Tauceri 1, Valentina Zucchini 2, Eleonora Pozzi 2, Leonardo Solaini 1,2 and Giorgio Ercolani 1,2  \nCitation: D’Acapito, F.; Framarini, M.; Pietrantonio, D.D.; Tauceri, F.;  \nZucchini, V.; Pozzi, E.; Solaini, L.; Ercolani, G. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Cancer with Peritoneal Metastasis: A Single-Center Cohort Study. Medicina 2024, 60, 1058 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)medicina60071058  \nAcademic Editor: Shinobu Ohnuma  \nReceived: 25 May 2024  \nRevised: 20 June 2024  \nAccepted: 25 June 2024  \nPublished: 27 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Forlanini 34, 47121 Forlì, Italy; [daniela.dipietrantonio@auslromagna.it](daniela.dipietrantonio@auslromagna.it) (D.D.P.); [francesca.tauceri@auslromagna.it](francesca.tauceri@auslromagna.it) (F.T.); [leonardo.solaini2@unibo.it](leonardo.solaini2@unibo.it) (L.S.); [giorgio.ercolani2@unibo.it](giorgio.ercolani2@unibo.it) (G.E.)  \n2 Department of Medical and Surgical Sciences, University of Bologna, Via Zamboni 33, 40126 Bologna, Italy; [valentina.zucchini4@studio.unibo.it](valentina.zucchini4@studio.unibo.it) (V.Z.); [eleonora.pozzi3@studio.unibo.it](eleonora.pozzi3@studio.unibo.it) (E.P.)  \n* Correspondence: [fabrizioda@gmail.com](fabrizioda@gmail.com); Tel.: +39-0543735500  \nAbstract: Multimodal treatment in peritoneal metastases (PM) from colorectal neoplasms may improve overall survival (OS) . In this study, we reported our experience in using cytoreductive surgery (CRS) combined with intraperitoneal chemohyperthermia (HIPEC) for the treatment of peritoneal metastases (PM) from colorectal neoplasms. The first aim was to evaluate the overall survival of these patients. Furthermore, using the results of the Prodige 7 Trial and incorporating them with the entropy balance statistical tool, we generated a pseudopopulation on which to test the use of CRS alone. We performed a retrospective analysis based on a prospective database of all 55 patients treated with CRS + HIPEC between March 2004 and January 2023 . The median OS was 47 months, with 1-, 3-and 5-year survival rates of 90.8%, 58.7% and 42.7%, respectively. There was no significant difference in the data in the pseudogroup generated with entropy balance. This finding confirms the critical role of complete cytoreduction in achieving the best OS for patients with PM. PCI > 6 seems to be the most important prognostic factor influencing OS. At present, CRS + HIPEC seems to be the therapeutic strategy that guarantees the best results in terms of OS for patients with relatively low PCI and in whom a CCS ≤ 1 can be achieved.  \nKeywords: hyperthermic intraperitoneal chemotherapy; peritoneal metastases; colorectal cancer; cytoreductive surgery; outcome  \n1. Introduction  \nColorectal cancer (CRC) ranks third in terms of incidence worldwide and second in terms of mortality [1] . When diagnosed early, approximately 80% of patients are eligible for surgery with curative intent [2] . Colorectal cancer (CRC) ranks third in terms of incidence worldwide and second in terms of mortality [1] Half of these patients present with metastases at diagnosis, sometimes multifocal [3,4] . The most likely sites for CRC to metastasize are the liver and the lungs [5], ","cbCaim2xXooyesow","https://ap.wps.com/l/cbCaim2xXooyesow","pdf",1557102,"English","# Introduction\n## Study overview and rationale\n## CRS and HIPEC background\n# Methods\n## Patient cohort and study design\n## Entropy-balance pseudopopulation\n# Results\n## Overall survival and survival rates\n## Prognostic factors and PCI/CCS considerations\n# Conclusion","[{\"question\":\"What treatment combination was evaluated for colorectal cancer patients with peritoneal metastases?\",\"answer\":\"The study evaluated cytoreductive surgery (CRS) combined with intraperitoneal chemohyperthermia (HIPEC) as a multimodal strategy for peritoneal metastases from colorectal neoplasms.\"},{\"question\":\"How was overall survival (OS) assessed and what were the key survival outcomes?\",\"answer\":\"Overall survival was evaluated in a retrospective analysis of 55 treated patients. Median OS was 47 months, with 1-, 3-, and 5-year survival rates of 90.8%, 58.7%, and 42.7%, respectively.\"},{\"question\":\"What does the study suggest about prognostic factors such as PCI and completeness of cytoreduction?\",\"answer\":\"The findings emphasize the critical role of complete cytoreduction to achieve the best OS. PCI \\u003e 6 was identified as the most important prognostic factor influencing OS, and best results were described for relatively low PCI when a CCS ≤ 1 could be achieved.\"}]","Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Cancer with Peritoneal Metastasis - A Single-Center Cohort Study | PDF",1790015364,25]